0001493152-26-022719
SEC filingPre-revenue biotech narrowing losses as it pivots from Rx to DTC skincare, but cash burn and going concern uncertainty persist ahead of mid-2026 launch.
Net cash used in operating activities increased to $2.5 million in Q1 2026 from $1.9 million in Q1 2025, driven by inventory build-up for the planned mid-2026 Tome launch. The company has taken steps to secure inventory of Spongilla raw material and believes it has sufficient quantities to support initial commercialization. Management continues to evaluate additional inventory procurement opportunities and manufacturing planning activities to support future commercial demand.
Management explicitly states there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date. The existing cash runway is expected to fund operations only into Q1 2027, and the company has no revenue, no approved products, and no committed financing beyond the now-exhausted ATM. The Tome launch, targeted for mid-2026, is the sole near-term catalyst for potential revenue, but management cautions that it is uncertain when—or if—the company will generate operating income. Additional capital will be required to sustain operations, and the company faces headwinds including a pending lawsuit from former licensor Villani (which obtained a temporary restraining order on certain advertising claims), sole-supplier concentration risk with Russian entity Reka-Farm for Spongilla raw material, and the inherent uncertainty of consumer adoption in a competitive skincare market.
Diluted EPS declined to $(0.48) from $(0.45), a 6.7% year-over-year decrease, as the improvement in net income was outweighed by a higher share count. The company raised capital through ATM and PIPE financings during the quarter, increasing the number of shares outstanding.